Published by Iain Gilbert on 15th September 2026
(Sharecast News) - Analysts at Berenberg upgraded drugmaker GSK from 'hold' to 'buy' on Tuesday and lifted their target price on the stock from £20 to £22, saying recent business‑development activity and pipeline momentum had strengthened the firm's long‑term growth outlook and left its valuation discount looking excessive.